Literature DB >> 8382510

Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging.

P L Olive1, J P Banáth, H H Evans.   

Abstract

Cells from V79 multicell spheroids must be exposed to approximately 50 times more etoposide than exponentially growing monolayers in order to produce the same amount of cell killing. A part of this difference in sensitivity is readily explained by the decrease in growth fraction of large spheroids, and by the protection afforded by nutrient deprivation which also reduces cellular ATP. However, cells composing the outer 10% of large (approximately 600 microns diameter) V79 spheroids, although actively cycling, were still ten times more resistant to etoposide than exponentially growing monolayers, regardless of whether cells were exposed in situ in spheroids or dispersed by trypsin immediately prior to exposure to the drug. Four cell doublings (48 h) as monolayers were required before the outer cells of spheroids regained drug sensitivity equivalent to that of exponentially growing monolayers. No differences in uptake/efflux of 3H-etoposide or in levels of p-glycoprotein were observed between monolayers and the outer cells of spheroids. In addition, topoisomerase II protein measured by immunoblotting and topoisomerase II activity measured by decatenation of kinetoplast DNA were not reduced in the outer cells of spheroids compared to monolayers. DNA strand breakage measured in individual cells using the DNA precipitation and comet assays correlated well with cell killing with one exception: DNA damage was not affected when cells were incubated with etoposide in phosphate-buffered saline, although the etoposide concentration required to produce a given amount of cell killing was increased approximately 7-fold compared to cells incubated with the drug in complete medium. These results indicate that etoposide toxicity towards V79 spheroids is influenced not only by proliferative status of the cells but also by factors which may include DNA packaging and the growth environment of the cell prior to and during treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382510      PMCID: PMC1968270          DOI: 10.1038/bjc.1993.97

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

1.  Topoisomerase-specific drug sensitivity in relation to cell cycle progression.

Authors:  K C Chow; W E Ross
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

2.  Involvement of intracellular ATP in cytotoxicity of topoisomerase II-targetting antitumor drugs.

Authors:  G Kupfer; A L Bodley; L F Liu
Journal:  NCI Monogr       Date:  1987

3.  Radiation-induced DNA unwinding is influenced by cell shape and trypsin.

Authors:  P L Olive; S H MacPhail
Journal:  Radiat Res       Date:  1992-05       Impact factor: 2.841

4.  Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment.

Authors:  R E Durand
Journal:  J Natl Cancer Inst       Date:  1986-07       Impact factor: 13.506

5.  A quantitative decatenation assay for type II topoisomerases.

Authors:  B M Sahai; J G Kaplan
Journal:  Anal Biochem       Date:  1986-08-01       Impact factor: 3.365

6.  Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells.

Authors:  Y H Hsiang; H Y Wu; L F Liu
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

7.  Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules.

Authors:  N Haim; J Nemec; J Roman; B K Sinha
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

8.  Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts.

Authors:  P J Smith; C O Anderson; J V Watson
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

9.  Cell and environment interactions in tumor microregions: the multicell spheroid model.

Authors:  R M Sutherland
Journal:  Science       Date:  1988-04-08       Impact factor: 47.728

10.  Topoisomerase II: A specific marker for cell proliferation.

Authors:  M M Heck; W C Earnshaw
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

View more
  8 in total

1.  Cytotoxic and biochemical implications of combining AZT and AG-331.

Authors:  J Pressacco; B Mitrovski; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 2.  Drug and radiation resistance in spheroids: cell contact and kinetics.

Authors:  P L Olive; R E Durand
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

3.  Identification of three gene candidates for multicellular resistance in colon carcinoma.

Authors:  Nicholas E Timmins; Tina L Maguire; Sean M Grimmond; Lars K Nielsen
Journal:  Cytotechnology       Date:  2005-06-16       Impact factor: 2.058

4.  Use of the comet assay for assessment of drug resistance and its modulation in vivo.

Authors:  P Huang; P L Olive; R E Durand
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases.

Authors:  J M Barret; B T Hill; P L Olive
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

Review 6.  Challenges of applying multicellular tumor spheroids in preclinical phase.

Authors:  Se Jik Han; Sangwoo Kwon; Kyung Sook Kim
Journal:  Cancer Cell Int       Date:  2021-03-04       Impact factor: 5.722

7.  Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.

Authors:  P L Olive
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

8.  Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines.

Authors:  Raúl Barrera-Rodríguez; Jorge Morales Fuentes
Journal:  Cancer Cell Int       Date:  2015-04-24       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.